J. Kevin Buchi

This profile gathers the share dealings of J. Kevin Buchi across 6 companies, led by Amneal Pharmaceuticals, Inc., Ampio Pharmaceuticals, Inc. and Benitec Biopharma Inc. We count 29 filings; the first trade dates from 23 November 2016 and the latest from 17 September 2026.

Purchases make up the whole of the open-market record (6 purchases, €36k). The amount is not disclosed for 1 filing. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 4 share grants and 11 option exercises.

In size, the median ticket on the buying side is €6,863. Clusters matter here: 5 out of 6 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. After 5 purchases with a full 90-day history, the hit rate stands at 0% and the median 90-day move at -24.5%. They describe history only and say nothing certain about the share price ahead.

Most recently, on 21 September 2026, the filings show a transaction in Amneal Pharmaceuticals, Inc. The last purchase on record was published on 14 August 2023, which is 1,167 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.